Nexentis Amends All Outstanding Warrants to Equity Classification to Regain Nasdaq Compliance
NXTS sits 21% above its 52-week low of $1.14 on light trading volume (0.1× avg).
Summary
Nexentis amended all outstanding warrants to achieve equity classification, a non-cash accounting change designed to help regain Nasdaq compliance after a September 3 deficiency notice.
Key Events · Corporate Governance and Compliance · NXTS
-
Warrant Amendments Effective September 29
All outstanding warrants — including the 1.85M-share L.I.A. Pure Capital warrant and June 2026 private placement warrants — were amended and restated to remove liability-classification provisions and qualify for equity classification.
-
Nasdaq Compliance Effort
The amendments were made specifically to regain compliance with Nasdaq Listing Rule 5550(b)(1), following the September 3 deficiency notice for falling below the $2.5M minimum stockholders' equity requirement.
-
No New Dilution or Consideration
The amendments did not increase the number of shares issuable, extend warrant terms, or provide additional economic consideration to holders — a purely accounting-driven change.
-
Facility Agreement Section Deleted
Section 8.2 of the Amended and Restated Facility Agreement with L.I.A. Pure Capital Ltd. was deleted in its entirety as part of the amendment.
Analysis · NXTS · Life Sciences
Nexentis amended every outstanding warrant — including the 1.85M-share L.I.A. Pure Capital warrant and the June 2026 private placement warrants — to remove provisions that forced liability accounting. The goal is equity classification, which directly addresses the Nasdaq deficiency notice received September 3 for falling below the $2.5M minimum stockholders' equity requirement. This is a non-cash accounting fix: no new shares, no extended terms, no additional consideration to holders. But it is a critical step in the company's fight to stay listed, coming one day after the preliminary proxy seeking approval to issue up to 20 million shares at up to a 20% discount — both moves aimed at shoring up the balance sheet and regaining compliance.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 29% of the 1517 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.52%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTS was trading at $1.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2M. The 52-week trading range was $1.14 to $49.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.